Pain-Free, Non-Surgical Laser Treatment Options MELBOURNE, Fla. (PRWEB) July 25, 2018 We are pleased to announce New York College of Podiatric Medicine (NYCPM) & Foot Center of New York’s (FCNY) acquisition of several Erchonia low-level lasers, including both Lunula Lasers and FX 635 Lasers. NYCPM provides unrivaled excellence in podiatric medical education and clinical… Read more »
FDA Market Clears Erchonia’s FX 635 Laser for Chronic Low Back Pain
First and Only FDA Market Cleared Low-Level Laser Treatment Option Melbourne, FL (PRWEB) July 17, 2018 Erchonia Corporation announces another successful clinical trial that has resulted in the granting of an FDA 510(k) market clearance for chronic low back pain of musculoskeletal origin. This grants another first for Erchonia, which started the low-level laser category… Read more »
WHAT STUDIES SAY ABOUT CLASS IV LASERS & SPECIFICALLY, THEIR IMPACT ON CANCER CELLS
The National Cancer Institute (NCI) reports that 39.6 percent of all Americans will receive a cancer diagnosis at some point in their lives. The NCI goes on to explain that cancer is one of the top causes of death across the globe, with new diagnoses expected to increase twofold-from 14 million… Read more »
